Filing Details

Accession Number:
0001140361-13-046219
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-12-13 19:42:48
Reporting Period:
2013-12-11
Filing Date:
2013-12-13
Accepted Time:
2013-12-13 19:42:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
69499 Mylan Inc. MYL Pharmaceutical Preparations (2834) 251211621
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197539 L Randall Vanderveen 1500 Corporate Drive
Canonsburg PA 15317
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-12-11 2,052 $14.82 29,488 No 4 M Direct
Common Stock Disposition 2013-12-11 2,052 $42.28 27,436 No 4 S Direct
Common Stock Acquisiton 2013-12-12 7,948 $14.82 35,384 No 4 M Direct
Common Stock Disposition 2013-12-12 7,948 $42.00 27,436 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Right to Buy Disposition 2013-12-11 2,052 $0.00 2,052 $14.82
Common Stock Stock Option Right to Buy Disposition 2013-12-12 7,948 $0.00 7,948 $14.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,948 2004-07-30 2014-07-30 No 4 M Direct
0 2004-07-30 2014-07-30 No 4 M Direct
Footnotes
  1. Represents the weighted average price of the reporting person's disposition of 2,052 shares in transactions ranging from $42.00 to $42.45.
  2. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
  3. This option exercise and the related sale of the underlying common stock were executed pursuant to a 10b5-1 trading plan dated November 25, 2013.